[Experience with the intrathecal use of liposomal cytarabine at the Besta Institute].
Istituto Nazionale Neurologico Carlo Besta, Milano.
Antonio
A
Silvani
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001254:Astrocytoma / Q000150:complications / Q000188:drug therapy; D001932:Brain Neoplasms / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000150:complications / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy; D002528:Cerebellar Neoplasms / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D008081:Liposomes; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008527:Medulloblastoma / Q000150:complications / Q000188:drug therapy*; D008581:Meningitis / Q000188:drug therapy* / Q000209:etiology; D018242:Neuroectodermal Tumors, Primitive / Q000150:complications / Q000188:drug therapy; D010166:Palliative Care; D011446:Prospective Studies; D012189:Retrospective Studies; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D008081:Liposomes; D003561:Cytarabine